8-K: Celularity Secures $2 Million Through Private Placement of Stock and Warrants

Celularity Inc. has entered into a private placement agreement with an institutional investor to raise $2 million through the sale of Class A common stock and accompanying warrants.

Summary

• Celularity Inc. entered into a Securities Purchase Agreement on July 14, 2025, with an institutional investor for a private placement.
• The private placement involves the issuance and sale of 1,230,769 shares of Class A common stock and warrants to purchase an equal number of shares (1,230,769).
• The purchase price for each share of Common Stock and Warrant is $1.625.
• The warrants are exercisable for two years from the date of issuance at an exercise price of $1.50 per share.
• Gross proceeds from this private placement are expected to be $2,000,000, before deducting estimated offering expenses.
• Net proceeds from the private placement are intended for working capital and general corporate purposes.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While securing $2 million in capital is positive for a development-stage company, the low share price and the issuance of warrants suggest a financing need under potentially dilutive terms. The company's acknowledgment of potential negative market impact from purchaser hedging activities also introduces a cautionary element.

Positives

• Successfully secured $2 million in gross proceeds, providing essential capital for operations.
• Funds are allocated for working capital and general corporate purposes, supporting ongoing business activities.
• The transaction involves an institutional investor, indicating some level of confidence from sophisticated market participants.

Negatives

• The issuance of new shares and warrants will result in dilution for existing shareholders.
• The purchase price of $1.625 per share and the warrant exercise price of $1.50 per share are relatively low, potentially reflecting a challenging valuation environment.
• The company acknowledges that purchaser hedging activities, including short sales, could negatively impact the market price of its publicly-traded securities.

Risks

• Potential negative impact on the market price of common stock due to hedging activities by the purchaser, including short sales.
• Future dilution from the exercise of the newly issued warrants.
• Risks associated with unregistered securities and reliance on exemptions from registration requirements.
• General risks inherent in the company's business, as detailed in its SEC reports, which could affect its ability to utilize the proceeds effectively or achieve profitability.

Future Outlook

The company intends to use the net proceeds from the private placement for working capital and general corporate purposes. It also commits to timely filing all required reports under the Exchange Act and maintaining the listing of its common stock on Nasdaq, including applying to list the newly issued shares.

Management Comments

• Robert J. Hariri, M.D., Ph.D., Chairman and CEO, signed the report on behalf of Celularity Inc. No specific forward-looking statements or opinions from management regarding the transaction's implications were provided in the filing beyond the legal disclosures.

Industry Context

For biotechnology and pharmaceutical companies, especially those in development stages without significant revenue, capital raises are a critical and frequent necessity to fund research and development, clinical trials, and operational expenses. Private placements, like this one, are a common method for such companies to secure capital quickly, particularly when public market conditions or company-specific factors make broader public offerings less feasible or desirable.

Comparison to Industry Standards

• Private placements are a standard financing tool for development-stage biotechnology companies, which often require substantial capital to advance their pipelines.
• The terms of the raise, including the issuance of warrants alongside common stock, are typical for private placements in the biotech sector, often used to make the offering more attractive to investors.
• The per-share price and warrant exercise price are reflective of the company's current valuation and the market's assessment of its risk profile, common for companies without late-stage products or significant commercialization.

Stakeholder Impact

• Shareholders: Will experience dilution from the issuance of new common stock and potential further dilution upon the exercise of warrants. The company also noted that purchaser hedging activities, including short sales, could negatively impact the market price of the common stock.
• Company Operations: The capital infusion provides crucial working capital and funds for general corporate purposes, supporting ongoing research, development, and operational needs.

Next Steps

• The company will file a current report on Form 8-K with the SEC, including the transaction documents as exhibits.
• The company will apply to list all newly issued shares on The Nasdaq Stock Market LLC.
• The company will file a registration statement on Form S-1 for the resale of the shares within 30 calendar days of the agreement date.
• The company will use commercially reasonable efforts to cause the S-1 registration statement to become effective within 60 calendar days following the Closing Date.
• The institutional investor has a right to participate in future 'Subsequent Financings' by the company, subject to certain conditions and exclusions.

Key Dates

Recommendation

The capital raise provides necessary working capital for Celularity, which is crucial for a development-stage biotech company. However, the terms of the private placement, including the low share price and the issuance of warrants, suggest a financing need under potentially dilutive conditions. The company's acknowledgment of potential negative market impact from purchaser hedging activities also warrants caution. Given these factors, a 'hold' recommendation is appropriate, advising investors to monitor the company's progress in utilizing the funds and its ability to mitigate dilution and market price volatility.

Keywords

Celularity, CELU, Private Placement, Equity Financing, Warrants, Common Stock, Capital Raise, SEC Filing, 8-K, Institutional Investor, Dilution, Biotechnology, Pharmaceutical